Low tissue plasminogen activator relative to plasminogen activator inhibitor-1 as a marker of cardiac complication in children with Kawasaki disease

Clinical and Applied Thrombosis/Hemostasis

Volumn 7, Issue 3, 2001, Pages 214-218

  Sakai, Michio ^a   Asayama, Kohtaro ^a   Otabe, Hiroyuki ^b   Kohri, Takeo ^b   Shirahata, Akira ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b YOKOHAMA ROSAI HOSPITAL   (Japan)

Author keywords

Coronary heart disease; Fibrinolysis; Kawasaki disease

Indexed keywords

C REACTIVE PROTEIN; D DIMER; FIBRIN; FIBRINOGEN; IMMUNOGLOBULIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; CHILD; CLINICAL ARTICLE; CONVALESCENCE; DRUG INFUSION; ECHOCARDIOGRAPHY; FIBRINOLYSIS; HUMAN; ISCHEMIC HEART DISEASE; LEUKOCYTOSIS; MUCOCUTANEOUS LYMPH NODE SYNDROME; PRIORITY JOURNAL;

ACUTE DISEASE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHILD, PRESCHOOL; CONVALESCENCE; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOGEN; HEART DISEASES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFANT; LEUKOCYTE COUNT; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0034966637     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960100700306     Document Type: Article

References (27)

1. Kawasaki disease, New York
2. Results of the nationwide epidemiologic survey of Kawasaki disease in 1995 and 1996 in Japan
3. High-dose intravenous gamma globulin for Kawasaki disease
4. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome
5. Selective high dose gamma-globulin treatment in Kawasaki disease: Assessment of clinical aspects and cost effectiveness
6. Class II major histocompatibility antigen expression on coronary arterial endothelium in patients with Kawasaki disease
7. Activation of peripheral blood monocytes and macrophages in Kawasaki disease: Ultrastructural and imuunocytochemical investigation
8. Kawasaki disease difers from anaphylactoid purpura and measles with regard to tumor necrosis factor-a and interleukin-6 in serum
9. Increase of tissue factor and haemostatic molecular markers
10. Studies on blood coagulation and antithrombotic therapy in Kawasaki disease
11. The platelet function in acute febrile mucoculaneous lymph node syndrome and trial of prevention for thrombisis by antiplatelet agent
12. Vascular cell-derived fibrinolytic regulators and atherothrombotic vascular disorders
13. Coagulopathy and platelet activation in Kawasaki syndrome: Identification of patients at high risk for development of coronary artiery aneurysms
14. Effects of intravenous gamma-globulin on neutrophil function in Kawasaki disease
15. Thrombun stimulates tissue plasminogen activator release from cultured human endothelial cells
16. Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation
17. Interleukin 1 and lipopolusaccharide induce and inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells
18. The opposing effects of basic fibroblast growth factor and transforming growth factor beta on the regulation of plasminogen activator activity in capillary endothelial cells
19. Tumor necrosis factor increases the production of plasmonigen activator inhibitor in human endothelial cells in vitro and rats in vivo
20. Regulation of the fibrinolytic system of cultured human vascular endothelium by inerleukin 1
21. Isolation of tissue-type plasminogen activator inhibitor complexes from human plasma
22. Impaired acterial neointima formation in mice with disruption of the plasminogen gene
23. Receptor-independent plasminogen activation by urokinase-type plasminogen activator promotes and ademoviral PAI-1 gene transfer neointima formation in mice
24. A pathological role of increased expression of plasminogen activator inhibator-1 in human or animal disorders
25. Prothrombotic and fibrinolytic function of normal and perturbed endothelium
26. Plasminogen activator inhibitor 1 (PAI-1) in plasma: Its role in thrombotic disease
27. High incidence of angiotensin I-converting enzyme genotype II in Kawasaki disease patients with coronary aneurysm